Investment Thesis
Emmaus Life Sciences faces severe financial distress with negative stockholders' equity of -$59.5M, indicating the company is technically insolvent. The company is burning cash at an alarming rate (-$2.2M operating cash flow) while revenue has collapsed 43.7% year-over-year, and with only $293K in cash against $29.1M in long-term debt, insolvency risk is critical.
Strengths
- Exceptional gross margin of 92.8% demonstrates strong pricing power on products that generate sales
- Minimal capital expenditure requirements ($1K) suggests asset-light business model
- High gross profit of $8M on available revenue shows operational efficiency at production level
Risks
- Negative stockholders' equity of -$59.5M represents technical insolvency and likely covenant violations
- Catastrophic liquidity crisis with current ratio of 0.07x and only $293K cash against $80.2M total liabilities
- Revenue decline of 43.7% YoY combined with negative net margin of -64.4% indicates deteriorating market position and inability to cover operating costs
- Negative operating cash flow of -$2.2M and negative interest coverage ratio of -0.1x indicate inability to service debt obligations
- Zero insider trading activity in past 90 days may suggest lack of management confidence
Key Metrics to Watch
- Cash runway and monthly burn rate relative to remaining cash balance
- Debt restructuring negotiations or covenant amendment discussions
- Revenue stabilization or further decline trends
- Operating cash flow trajectory toward positive territory
- Equity infusion or financing announcements to address insolvency
Financial Metrics
Revenue
8.6M
Net Income
-5.5M
EPS (Diluted)
$-0.09
Free Cash Flow
-2.2M
Total Assets
20.8M
Cash
293.0K
Profitability Ratios
Gross Margin
92.8%
Operating Margin
-7.6%
Net Margin
-64.4%
ROE
N/A
ROA
-26.7%
FCF Margin
-25.8%
Balance Sheet & Liquidity
Current Ratio
0.07x
Quick Ratio
0.06x
Debt/Equity
N/A
Debt/Assets
386.6%
Interest Coverage
-0.13x
Long-term Debt
29.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T06:54:11.847177 |
Data as of: 2025-09-30 |
Powered by Claude AI